{"publication_id":"21652f17-8a22-4863-aa37-ec5f4e1a7b90","screening":{"identified":28,"screened":28,"excluded":0,"included":28,"included_or_retained":28,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"28 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["This paper synthesizes evidence on Therapeutic plasma exchange across 28 accepted source papers and 1449 high-confidence extracted claims. The evidence profile contains 4 direct clinical sources, 24 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base. No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, immune and inflammation, safety and comorbidity outcome classes, and negative signals cluster in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that Therapeutic plasma exchange remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","The conclusion is that Therapeutic plasma exchange remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","Fuentealba 2025: Multi‐Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single‐Blinded Randomized Placebo‐Controlled Therapeutic Plasma Exchange: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; finding=representative statistic p < 0.048; source-level statistic reported."]}